Sabina Halappanavar, Adjunct Professor, Department of Biology, The University of Ottawa, Canada, email@example.com
Sarah Søs Poulsen, Post.Doc, National Research Centre for the Working Environment (NRCWE), Denmark, firstname.lastname@example.org
Adverse outcome pathways (AOPs) are the systematic and simplistic representation of a sequence of biological events that occur following toxicant exposure linking an early molecular initiating event to an adverse outcome at a biological level of organization relevant to risk assessment. The many uses of AOPs include:
- Identification of knowledge gaps in mechanistic understanding of toxicity,
- Design of alternative in vitro predictive assays and testing strategies to help inform risk assessment,
- Reducing reliance on animal use and,
- The development of biomarkers. Thus, well-defined AOPs that are specific to nanomaterials can help identify the data gaps and guide the future research priorities.
As a valuable aid in the construction of AOPs, toxicogenomics can be used to identify toxicity pathways or perturbed biology in response to different classes of substances. This knowledge can then be used to derive dose-response, identifying appropriate biological models pertinent to assessing the adverse outcome, and establishment of high throughput assays for screening or prioritizing.
- Developing an adverse outcome pathway based on toxicogenomic data for ENM-induced risk of developing atherosclerotic plaques – Invited presentation
Sarah Søs Poulsen
- Utilizing an adverse outcome pathway framework to investigate the essentiality of Interleukin and STAT signaling in the pathology of a carbon nanotube in mice – Invited presentation
- TiO2-induced gene expression and protein profiles in rat lung: a subacute inhalation study
- Nanomaterial impact on models of asthma and allergic airway disease: mechanistic insight as an aid for hazard assessment
- Proteomic analysis of nasal lavage samples collected from welders experimentally exposed to welding fume nanoparticles